Investment and strategic partnerships are the lifeblood of innovation in healthcare, driving groundbreaking discoveries and ...

Onsite at the Boehringer Ingelheim R&D centre in Biberach, Germany, the conversation also circled around Boehringer’s One Medicine Project, originally announced in March 2022, but the central focus ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.

With a three-decade-plus journey in the oncology space, Hevia and Sousa spoke to the company’s developments in lung, bladder, and colorectal cancer, as announced at both ESMO and WCLC, as well as what ...

With only 12% 1 of therapies surviving the gauntlet of Phase III trials to receive FDA approval, and the cost to bring a drug ...

The approach can be transformative. When patients feel heard and understood, they’re more likely to engage actively and ...

If approved, the six manufacturers – Dr Reddy’s Laboratories Limited, Emcure, Eva Pharma, Ferozsons Laboratories Limited, ...

A new report commissioned by the Association of the British Pharmaceutical Industry (ABPI) has found that hospitals engaging ...

HALIX, a Dutch contract development and manufacturing organisation (CDMO) specialising in complex therapeutic antibodies and ...

During pilot programmes, Concentriq Embeddings demonstrated its ability to significantly accelerate AI development. In one ...